Abstract

The aging-protective gene α-Klotho (KL) produces two main transcripts. The full-length mRNA generates a transmembrane protein that after proteolytic ectodomain shedding can be detected in serum as processed Klotho (p-KL), and a shorter transcript which codes for a putatively secreted protein (s-KL). Both isoforms exhibit potent pleiotropic beneficial properties, although previous reports showed negative side effects on mineral homeostasis after increasing p-KL concentration exogenously. Here, we expressed independently both isoforms using gene transfer vectors, to assess s-KL effects on mineral metabolism. While mice treated with p-KL presented altered expression of several kidney ion channels, as well as altered levels of Pi and Ca2+ in blood, s-KL treated mice had levels comparable to Null-treated control mice. Besides, bone gene expression of Fgf23 showed a fourfold increase after p-KL treatment, effects not observed with the s-KL isoform. Similarly, bone microstructure parameters of p-KL-treated mice were significantly worse than in control animals, while this was not observed for s-KL, which showed an unexpected increase in trabecular thickness and cortical mineral density. As a conclusion, s-KL (but not p-KL) is a safe therapeutic strategy to exploit KL anti-aging protective effects, presenting no apparent negative effects over mineral metabolism and bone microstructure.

Details

Title
Differential toxicity profile of secreted and processed α-Klotho expression over mineral metabolism and bone microstructure
Author
Roig-Soriano, Joan 1   VIAFID ORCID Logo  ; Sánchez-de-Diego, Cristina 2   VIAFID ORCID Logo  ; Esandi-Jauregui, Jon 1   VIAFID ORCID Logo  ; Verdés, Sergi 1   VIAFID ORCID Logo  ; Abraham, Carmela R. 3   VIAFID ORCID Logo  ; Bosch, Assumpció 4   VIAFID ORCID Logo  ; Ventura, Francesc 2   VIAFID ORCID Logo  ; Chillón, Miguel 5   VIAFID ORCID Logo 

 Universitat Autònoma Barcelona, Department of Biochemistry and Molecular Biology, Institut de Neurociènces (INc), Bellaterra, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625) 
 Universitat de Barcelona, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, IDIBELL, L’Hospitalet de Llobregat, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247) 
 Boston University School of Medicine, Departments of Biochemistry and Pharmacology & Experimental Therapeutics, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Universitat Autònoma Barcelona, Department of Biochemistry and Molecular Biology, Institut de Neurociènces (INc), Bellaterra, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain (GRID:grid.430994.3) (ISNI:0000 0004 1763 0287); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 Universitat Autònoma Barcelona, Department of Biochemistry and Molecular Biology, Institut de Neurociènces (INc), Bellaterra, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain (GRID:grid.430994.3) (ISNI:0000 0004 1763 0287); Universitat Autònoma Barcelona, Unitat Producció de Vectors (UPV), Bellaterra, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X) 
Pages
4211
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2786746983
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.